Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAILOR study of customized ibrutinib regimens in previously untreated chronic lymphocytic leukemia
2023-504044-34-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2 trial of ibrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Best objective response rate. Planned start Nov 2023; status: authorised.
02
Drugs
ibrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-504044-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504044-34-00.